Interim Report Q2 1 April

In the second quarter (1 July–30 September 2026), net sales rose 8% to SEK 5,907 million, while EBITA increased 17% to SEK 987 million and the EBITA margin improved to 16.7% from 15.5%. Operating profit also rose 17% to SEK 826 million, with the operating margin up to 14.0% from 13.0%. A non-recurring positive effect of around SEK 55 million in the Safety business area contributed to quarterly EBITA.

Analysis

The headline margin expansion overstates the quality of the quarter. Excluding the stated SEK 55m Safety benefit, EBITA is approximately SEK 932m: about 10% growth, with an implied margin near 15.8% versus 15.5% a year ago. That points to modest underlying margin progress, not the full reported 120bp expansion. The key market question is whether sales growth is organic and repeatable, and whether the normalized margin improvement reflects pricing/product mix or temporary cost effects; the data provided cannot distinguish these drivers.

Near term, the results may support a positive reaction, but that response is vulnerable to investors normalizing the one-off. Over the next 1–3 months, segment disclosure and management commentary on order intake, organic growth, and cost trends should matter more than the headline EBITA growth. Over 6–18 months, sustained normalized margin gains would support earnings-quality upgrades; flat normalized margins would leave the growth multiple unsupported. Company identity, valuation, consensus, and segment mix are not supplied, so no company-specific relative-value or competitor trade is justified.

Key Decisions for Investors

• Do not chase the reported margin expansion on these figures alone; treat approximately SEK 932m as a rough normalized EBITA reference, not company guidance.
• Before taking a directional position, verify the company identity and ticker, organic versus acquired/FX sales contribution, and whether the Safety benefit also affects operating profit or cash flow.
• Watch the next results and any interim trading update for order intake and normalized EBITA margin: sustained improvement alongside organic growth would strengthen the long case; margin slippage toward the prior-year level or weaker orders would falsify it.
• No standalone options or pair trade is warranted without valuation, consensus, and segment exposure data; reassess after those inputs are available.